Atara Biotherapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Adage Capital Management, L.P. and its principals have reported beneficial ownership of 8.56% of Atara Biotherapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 17.4% beneficial ownership stake in Atara Biotherapeutics, Inc.
NASDAQ
EcoR1 Capital, LLC and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Atara Biotherapeutics, Inc. common stock.
NASDAQ
SCHEDULE 13G/A: Redmile Group and Affiliates Disclose Significant 9.9% Stake in Atara Biotherapeutics, Inc.
Investment firm Redmile Group, along with its principal Jeremy C. Green and affiliated funds, has disclosed a combined beneficial ownership of 9.9% in Atara Biotherapeutics, Inc., including shares held directly and those issuable from pre-funded warrants.
NASDAQ
Panacea Venture Healthcare Fund II, L.P. and its affiliated entities have disclosed a 9.5% passive beneficial ownership stake in Atara Biotherapeutics, Inc., holding 550,000 shares of common stock.